SFSD 2022 – Telemonitoring, at the heart of oncology recommendations

Paris, France – During the congress of the French Society of Digital Healthwhich took place in Paris on October 5 and 6, 2022, a round table discussed the most promising e-health innovations. [1] Fabrice Denis (oncologist, Le Mans) described how telemonitoring was now fully recognized in oncology. In practice, patients in his department treated for cancer use a tool through which they complete (alone or with a caregiver) a standardized questionnaire on their symptoms. These data pass through an algorithmic filter which, if necessary, transmits an alert to the team which usually monitors them, according to the data declared. ” This type of tool makes it possible to manage toxicity by early identification of adverse effects and therefore reduce the risk of hospitalization “, insisted the oncologist.

International guidelines now incorporate electronic patient-reported quality of life measures (PROMs) as an effective remote monitoring tool. Thus, those of ESMO, published last spring, recommend that all patients have recourse to these tools (e-PROMS) on the basis of eight randomized studies available today, which describe a benefit of this type of tool on quality of life, symptom reduction or survival, compared to patients who do not use them. Also, it seems essential to propose them, even if two elements will have to be resolved to generalize them, he acknowledged: an organization of the services making it possible to integrate these new methods of monitoring and management of alerts and, on the other hand hand, the question of financial support for the tool.

“These tools are not intended to take precedence over medical care”, also insisted the specialist. Indeed, as a randomized study has shown, remote monitoring provides better clinical results when the action to be taken in the face of alerts is managed by a medical team compared to cases where it is indicated to the patient by the digital tool itself. same. ” You can’t delegate everything to a machine. “, wanted to reassure Fabrice Denis, recalling that it is not a question of artificial intelligence, but of “simple” algorithms for the systematized collection of information which are more exhaustive and systematic than those carried out by doctors.

Finally, the specialist mentioned the limits specific to the patient himself: questions of the reliability of self-declaration first of all, which ultimately turn out not to be, once the questionnaires used have been validated. Patient adherence, meanwhile, is generally good, at around 80%, which is generally satisfactory. ” The real problem of reliability could on the other hand come from the algorithm », recognizes Fabrice Denis. ” Because if a tool is effective at a time T, it may no longer be relevant if the recommended course of care has been modified in the meantime. The question of regularly reassessing the tools, and updating them if necessary, is crucial.

This article originally appeared on Univadis.frmember of the Medscape network

Follow Medscape in French on Twitter.

Follow theheart.org | Medscape Cardiology on Twitter.

Subscribe to Medscape Newsletters : select your choices

We want to give thanks to the writer of this post for this amazing content

SFSD 2022 – Telemonitoring, at the heart of oncology recommendations

Visit our social media accounts and other related pageshttps://www.ai-magazine.com/related-pages/